Search
Aprobarbital
go.drugbank.com/drugs/DB01352ExperimentalIllicitAprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects.
Exametazime
go.drugbank.com/drugs/DB11179ApprovedIt is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes. … It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex.
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.
Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineNebicapone
go.drugbank.com/drugs/DB14849InvestigationalNebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose
Bumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Paquinimod
go.drugbank.com/drugs/DB13118InvestigationalThe disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.
Tyramine
go.drugbank.com/drugs/DB08841InvestigationalNutraceuticalThere have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.